(1)
SpyBiotech has raised $32.5M from leading investors to advance development of its novel plug and display vaccine platform technology
Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors Oxford Sciences Innovation and GV also participated
Lutz B. Giebel joins as Chairman, strengthening governance as company expands clinical development and builds operational resource
OXFORD, United Kingdom, Feb. 10, 2021 (GLOBE NEWSWIRE) SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces it has raised $32.5 million in Series A equity financing and appointed Lutz B. Giebel as Chairman.
Investegate announcements from SpyBiotech, SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
Sygnia Asset Management is developing a new vaccine and South Africans are once again connecting the dots between CEO Magda Wierzycka and President Cyril Ramaphosa.
Sygnia, an investor in Oxford Sciences Innovation, approached the Serum Institute of India (SII) to run trials on a new set of jabs. The aim is to produce 10 million inoculations for South Africa citizens.
Magda Wierzycka, Ramaphosa and the vaccine
Vaccine battle
Earlier this week, Wierzycka told
Moneyweb editor Ryk van Niekerk that the Ministry of Health should use AstraZeneca on medical personnel in order to have a “larger sample size to observe on a live basis”.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
PepGen Announces Appointment of James McArthur, Ph.D., as President and Chief Executive Officer
February 4, 2021 GMT
PepGen Logo
BOSTON and OXFORD, England, Feb. 4, 2021 /PRNewswire/ PepGen, a biotechnology company focused on transforming the care of patients with neuromuscular diseases through the enhanced delivery of therapeutic oligonucleotides, today announced the appointment of James McArthur, Ph.D., as President and Chief Executive Officer (CEO). Dr. McArthur brings more than 25 years of experience as a co-founder of numerous biotech companies focused on rare disease therapeutics. He joins the PepGen team at a time of rapid growth following its successful $45 million Series A financing at the end of 2020, which was led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), CureDuchenne Ventures, and the University of Oxford.
DGAP-News: Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
Scenic Biotech BV: Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman
02.02.2021 / 09:30
PRESS RELEASE
- Dr. Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience
- Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn
- Joins at a key juncture in Scenic Biotech s strategic growth, building its pipeline of genetic modifier drug candidates
Amsterdam, The Netherlands, 2 February, 2021 - Scenic Biotech BV ( Scenic ), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Dr. Philippe Dro as its independent Chairman. A highly experienced entrepreneur, he replaces Dr. Ulrich Grau who retires from the Board of Directors.